SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as the community reacts to a proposed flat Medicare Advantage payment rate from the Trump administration, significantly below market expectations. This news, surfacing just ahead of upcoming earnings, has fueled widespread debate among investors about potential market manipulation and the broader implications for the healthcare sector, leading to active 'buy the dip' discussions amidst heightened volatility.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending sharply higher after news that renowned investor Michael Burry has been actively buying shares, signaling his belief in CEO Ryan Cohen's long-term strategy. This "smart money" endorsement, coupled with recent insider buys, is fueling intense community discussion and a surge in trading volume, with many hoping for a potential resurgence reminiscent of past events.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth Inc. (USAR) is trending following a significant U.S. government investment and a private placement, which the community views as a major catalyst for accelerating domestic rare earth supply chain development and national security. Investors are actively discussing its potential for considerable growth, drawing comparisons to other government-backed entities, though some are cautious about market manipulation and potential share dilution after its notable price movements. This strategic funding aims to bolster U.S. independence in critical minerals, positioning USAR as a key player in the sector.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is generating intense discussion due to an abrupt CFO transition and recent analyst downgrades, which have contributed to the stock hitting multi-year lows. The community is sharply divided, with many expressing frustration over management's perceived silence and the company's sustained underperformance amidst fierce competition from "walled garden" platforms. Despite calls for CEO accountability and fears of further declines, some investors view the current valuation as an attractive entry point, highlighting the company's strong fundamentals and the potential for a rebound in the ad-tech sector.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver ($AGQ) is trending amid intense community debate, primarily fueled by discussions around a global silver supply shortage and recent Chinese export restrictions impacting worldwide supply. Bulls anticipate a continued "parabolic" rally driven by industrial demand, while skeptics warn of "pure euphoria" and potential for a significant "rug pull," highlighting the amplified volatility in this leveraged ETF.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is actively discussed after recent proposals for flat Medicare Advantage payment rates and a reported lawsuit loss challenging past bonus cuts sparked significant volatility in the stock. The community remains divided, with many seeing current valuations as a compelling buying opportunity amid broader concerns about government policy and rising costs impacting the healthcare insurance sector.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing intense volatility after silver surged past historic price levels, driven by strong industrial demand from sectors like AI and EVs, alongside geopolitical uncertainty. The community is sharply divided between bulls, who foresee further parabolic moves fueled by a significant Shanghai premium and perceived market manipulation, and bears, who anticipate a major pullback following recent price spikes and increased COMEX margin requirements. This ongoing debate underscores the market's current focus on silver's true valuation amidst these dynamic conditions.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS Health is trending right now due to the proposed flat Medicare Advantage payment rates for 2027, which has sparked widespread concern over potential margin compression across the broader managed care sector. While many in the community are reacting to the sharp decline, some investors are seizing the opportunity to buy into the downturn, betting on the company's long-term resilience.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom Video Communications, Inc.

Zoom is trending due to significant community discussion around its strategic investment in AI company Anthropic, now viewed as a multi-billion dollar "hidden gem." This, alongside recent strong earnings and the expanding adoption of its AI Companion features, has fueled optimism about the company's comeback and its future in the competitive AI-driven communications sector.

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Elevance Health Inc

Elevance Health is navigating market volatility as the healthcare sector responds to concerns over future Medicare payment rates and the ongoing debate surrounding Affordable Care Act subsidies. Despite ELV recently exceeding adjusted earnings expectations, community sentiment is divided between those viewing current valuations and strategic shifts as a compelling opportunity and those remaining cautious about broader industry headwinds and margin pressures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?

Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA...

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their...

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF...

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with...

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of...

Barinthus Biotherapeutics (BRNS) announced on Tuesday that it will merge with Clywedog Therapeutics in an all-stock transaction. Following the announcement, the company's shares slid 7% in the pre-market session.Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share (ADS) or ordinary share they own. Meanwhile, each stockholder of Clywedog will receive 4.358932 shares of common stock in the new combined company for every common or preferred share they own. The combined company will advance a fresh portfolio of three clinical-stage candidates targeting metabolic and autoimmune diseases, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.barinthusbio.com/news-releases/news-release-details/barinthus-biotherapeutics-combine-clywedog-therapeutics-target">said</a>. Four clinical data milestones are expected within 18 months of transaction closing, it added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BRNS">BRNS stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.The combined company will be renamed “Clywedog Therapeutics, Inc.” and is expected to trade on the Nasdaq under the new ticker symbol “CLYD.” Barinthus Bio ADSs will no longer trade on the Nasdaq following the closing of the transaction in the first half of 2026.The combined company will initially focus on advancing its pipeline in Type 1 diabetes, Type 2 diabetes, and celiac disease, Barinthus said. It is expected to have a cash runway into 2027 with additional investments from Clywedog’s existing investors, OrbiMed and Torrey Pines Investment LLC.Upon closing, shareholders of Barinthus Bio are expected to own approximately 34%, and the stockholders of Clywedog are expected to own approximately 66% of the combined company on a fully diluted basis.BRNS shares are up by 22% this year and 24% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-gets-price-target-hike-from-canaccord/chDD7JrR3Bq">Tesla Gets A Price Target Hike From Canaccord: Retail Sees Stock Touching New Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Barinthus Biotherapeutics To Merge With Privately-Held Clywedog Therapeutics

Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own.

Equity

Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own.


Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.

Barinthus Biotherapeutics Plc. - ADR

No change

25 bps cut

25 bps hike

Note sure, just watching

The Fed announces its rate decision this Wednesday.

Markets are pricing in a ~99% chance of no change at this week’s Fed decision, according to prediction markets. $SPY $QQQ 

FOMC on Wednesday, what do you think the Fed will decide?

BRNS
Barinthus Biotherapeutics PLC - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BRNS News

BRNSBarinthus Biotherapeutics PLC - ADR